New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
12:14 EDTIP, MOS, ADM, NVS, SCCOStocks with increasing implied volatility: NVS MOS SCCO ADM IP
News For NVS;MOS;SCCO;ADM;IP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 21, 2014
05:22 EDTNVSNovartis Cosentyx receives positive CHMP opinion
Subscribe for More Information
November 20, 2014
05:31 EDTIPInternational Paper initiated with a Market Perform at Wells Fargo
November 19, 2014
15:53 EDTADMADM sues Syngenta over China rejections of GMO corn, Reuters says
Subscribe for More Information
10:00 EDTMOSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:39 EDTMOSMosaic upgraded to Positive at Susquehanna
Subscribe for More Information
06:20 EDTMOSMosaic upgraded to Positive from Neutral at Susquehanna
Subscribe for More Information
November 18, 2014
10:41 EDTMOSFertilizer names rise after Uralkali suspends work at mine
Subscribe for More Information
10:15 EDTMOSHigh option volume stocks
Subscribe for More Information
November 17, 2014
16:52 EDTNVSNovartis' LCZ696 could change course of heart failure for patients, study shows
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction shows it has the potential to change the course of the disease for patients. In August, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. The new analyses being presented for the first time at the American Heart Association Scientific Sessions 2014, with a paper being simultaneously published in Circulation, show that versus enalapril, LCZ696 significantly: reduced the risk of dying suddenly by 20% in HFrEF patients 45% of CV deaths and 36% of all cause deaths are sudden; reduced first and subsequent HFrEF hospitalizations by 21% and 23% respectively; reduced hospitalizations for a cardiovascular reason or for any reason both by 16%; reduced the need for more intense treatment at home by 16%; reduced emergency room visits because of rapid symptom worsening by 30%.
11:06 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
November 14, 2014
14:53 EDTNVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTNVSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
13:32 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
12:26 EDTMOSKoch Industries reports new Colfax stake in quarterly filing
Subscribe for More Information
November 12, 2014
11:17 EDTNVSLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:18 EDTNVSUBS to hold a conference
Subscribe for More Information
07:58 EDTNVSGenVec expects 2014 cash burn between $6M-$7M from Novartis collaboration
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use